Linnea has been granted a narcotics license by Swissmedic at the end of 2022. The Company will begin producing GMP-certified high-THC active pharmaceutical ingredients (APIs) in 2023.
Gaining a narcotics license will allow Linnea to export their standardized and innovative high-THC APIs anywhere in the world where the importation of these products is legal. The demand for GMP-certified pharmaceutical-grade cannabis is higher than ever. With this license, Linnea will be able to meet the demand of customers and patients worldwide.
“We are so honored to be granted a narcotics license in Switzerland. This opens up many new commercial possibilities for Linnea Cannabinoids and our customers,” says Susanne Caspar, CEO of Linnea SA. “High-quality cannabinoid ingredients are essential to producing the pharmaceutical products that patients need, and we are eager to contribute our expertise to this effort. We look forward to the opportunities this will afford us in creating new partnerships and continuing to innovate in the industry.”
For more information:
Linnea
linnea.ch